Ovarian function suppression with a GnRH analogue: D-ser(But[t])[6]-Arzgly[10]-LHRH (Goserelin) in hormone dependent canine mammary cancer.

@article{Lombardi1999OvarianFS,
  title={Ovarian function suppression with a GnRH analogue: D-ser(But[t])[6]-Arzgly[10]-LHRH (Goserelin) in hormone dependent canine mammary cancer.},
  author={Pietro Lombardi and Salvatore Florio and Ugo Pagnini and Antonio Crispino and Luigi Avallone},
  journal={Journal of veterinary pharmacology and therapeutics},
  year={1999},
  volume={22 1},
  pages={
          56-61
        }
}
Hormones and hormone level modifying substances have long been used to treat hormone-dependent tumours in humans. Recently, attempts have been made to use hormone manipulation regimens for the treatment of these tumours in veterinary medicine. The aim of the present study was to evaluate the activity of the luteinizing hormone-releasing hormone (LHRH)-agonist, D-ser(But[t])[6]-Azgly[10]-LHRH (Goserelin) in hormone-dependent mammary cancer in dogs. Eighteen female dogs with hormone-dependent… 
GnRH and steroids in cancer.
TLDR
The present review elucidate the role of GnRH receptors in cancer and their connection with steroid hormones, and showed the link between GnRH and signal transductions pathways: Estrogen-receptors, GnRH-receptorors, EGF-receptionors signal transduction pathways.
Clinical and endocrine short-term effects of GnRH analogue deslorelin in prepubertal bitches: does a "flare-up" occur?
TLDR
Data demonstrate that in prepubertal bitches, insertion of a deslorelin implant does not cause a “flare-up effect” which commonly occurs in anestrus adult bitches during the first month after implantation.
The Effect of a Long-acting GnRH Agonist (Deslorelin) on Estrogen Receptor Alpha (ERα) and Progesterone Receptor (PR) Expressions in Canine Mammary Tissue
TLDR
The finding indicated that deslorelin may effect the expression of ERα and PR in the bitch mammary tissue, in which it may stimulate theexpression of ER α and PR at 2 weeks after des Lorelin implantation.
Clinical usage of GnRH agonists in small animal reproduction : a review
TLDR
There is evidence that GnRH agonists can be at least be partially effective in treating post-spaying urinary incontinence in the bitch, and other clinical applications which await confirmation include prevention of mammary tumor metastatic disease, treatment of androgen dependent diseases or treatment of azoospermia in dogs.
Direct effect of a gonadotropin‐releasing hormone agonist on the growth of canine mammary tumour cells
TLDR
The results of these “in vitro” studies show that GnRH‐A counteracts the mitogenic action of EGF and ATP, decreases the EGF/ATP‐induced calcium signalling and reduces EGF binding, probably by means of NO‐induced [Ca2+]i downregulation.
Reproductive use of the GnRH in cats and dogs.
TLDR
The structure of the GnRH analogues and their current use in cats and dogs are given and it is shown that although studies on reproduction in female Cats and dogs have increased, more research is needed.
New GnRH analogs in canine reproduction.
  • C. Gobello
  • Biology, Medicine
    Animal reproduction science
  • 2007
Clinical use of GnRH agonists in canine and feline species.
GnRH (gonadotrophin releasing hormone) is a key hormone of reproductive function in mammals; agonist forms have been largely developed, and data concerning their use in small animal reproduction are
The use of GnRH agonists implants in bitches and queens
GnRH (gonadotrophin releasing hormone) is a key hormone of reproductive function in mammals; agonist forms have been largely developed, and data concerning their use in small animal reproduction are
...
...

References

SHOWING 1-10 OF 27 REFERENCES
Ovarian Function Suppression with the Gonadotrophin-Releasing Hormone (GnRH) Analogue Goserelin in Premenopausal Advanced Breast Cancer
TLDR
It is confirmed that goserelin is as effective as surgical oophorectomy in premenopausal advanced breast cancer and the best responses were observed on soft tissues.
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders.
TLDR
The availability of depot goserelin has broadened the spectrum of effective treatments for benign estrogen-dependent gynaecological disorders and is effective as a sustained release depot formulation suitable for administration on a monthly basis.
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.
TLDR
Goserelin seems to be preferred to surgery by the majority of patients given a choice of treatment, and importantly in a palliative care situation where there are no survival advantages for treatment alternatives, it appears to have a more beneficial effect on the quality of life than surgery.
Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.
TLDR
It is concluded that combination treatment with an antiprogestin and an antiestrogen or an LHRH agonist may be of great value in the endocrine therapy of breast cancer.
Effect of chronic administration of a highly potent LHRH agonist on prostate size and secretory function in geriatric dogs
TLDR
The data suggests that LHRH agonists may have utility in the therapy of hormone‐responsive prostatic pathologies in geriatric male dogs of mixed breed.
Experience with a depot GnRH-agonist (Zoladex) in the treatment of genital endometriosis.
TLDR
All 57 symptomatic patients showed a subjective response to Zoladex therapy with a significant decrease of the total pelvic symptom score, and thirty-eight patients with infertility wished to become pregnant and so far 16 have conceived.
Luteinizing hormone releasing hormone, estrogen, and progesterone receptors in canine mammary lesions and tumor cell lines.
TLDR
The presence of functional hormone receptors in canine mammary tumors offers opportunity for hormonal treatment of mammary cancer which may not be completely treatable by surgery.
In vitro studies of canine mammary tumors: influence of 17-beta-estradiol and progesterone on cell kinetics parameters.
TLDR
This work has found a significantly positive relationship between the estrogen and the progesterone receptor concentrations and the basal proliferation rate in these tumors, whereas no correlation was found between steroid receptor contents and the maximal level of stimulation achieved after E2 or Pg exposure.
...
...